Beyond Air Gestione

Gestione criteri di controllo 3/4

Beyond Air Il CEO è Steve Lisi, nominato in Jun2017, e ha un mandato di 7.42 anni. la retribuzione annua totale è $ 1.73M, composta da 37.5% di stipendio e 62.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 4.5% delle azioni della società, per un valore di € 1.58M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 7 anni.

Informazioni chiave

Steve Lisi

Amministratore delegato

US$1.7m

Compenso totale

Percentuale dello stipendio del CEO	37.5%
Mandato del CEO	7.4yrs
Proprietà del CEO	4.5%
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Steve Lisi rispetto agli utili di Beyond Air?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$55m
Jun 30 2024	n/a	n/a	-US$58m
Mar 31 2024	US$2m	US$650k	-US$60m
Dec 31 2023	n/a	n/a	-US$67m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$59m
Mar 31 2023	US$7m	US$650k	-US$56m
Dec 31 2022	n/a	n/a	-US$56m
Sep 30 2022	n/a	n/a	-US$51m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	US$6m	US$450k	-US$43m
Dec 31 2021	n/a	n/a	-US$28m
Sep 30 2021	n/a	n/a	-US$26m
Jun 30 2021	n/a	n/a	-US$23m
Mar 31 2021	US$2m	US$450k	-US$23m
Dec 31 2020	n/a	n/a	-US$23m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	US$1m	US$450k	-US$20m
Dec 31 2019	n/a	n/a	-US$15m
Sep 30 2019	n/a	n/a	-US$13m
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	US$3m	US$450k	-US$7m
Dec 31 2018	n/a	n/a	-US$5m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$10m
Mar 31 2018	US$537k	US$130k	-US$11m
Dec 31 2017	US$2m	US$163k	-US$18m

Compensazione vs Mercato: La retribuzione totale di Steve ($USD 1.73M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 478.33K ).

Compensazione vs guadagni: La retribuzione di Steve è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Steve Lisi (53 yo)

7.4yrs

Mandato

US$1,733,000

Compensazione

Mr. Steven Adam Lisi, also known as Steve, has been the Chief Executive Officer of Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) since June 14, 2017. Mr. Lisi serves as Chief Executive Office...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Steven Lisi	CEO & Chairman of the Board	7.4yrs	US$1.73m	4.5% € 1.6m
Michael Gaul	Chief Operating Officer	2.3yrs	US$799.00k	0.090% € 31.7k
Amir Avniel	Chief Executive Officer of NeuroNOS	less than a year	US$952.00k	0% € 0
Douglas Larson	CFO, Principal Financial Officer & Principal Accounting Officer	3.2yrs	US$1.13m	0.026% € 9.0k
Edward Barger	Head of Investor Relations	no data	Nessun dato	Nessun dato
Andrew Colin	Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board	2.9yrs	Nessun dato	Nessun dato
David Webster	Chief Commercial Officer	less than a year	Nessun dato	Nessun dato
John Jett	Head of Research & Clinical Development	less than a year	Nessun dato	Nessun dato
Adam Newman	Corporate Secretary	no data	US$643.57k	Nessun dato

2.3yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di 48L è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Steven Lisi	CEO & Chairman of the Board	7.8yrs	US$1.73m	4.5% € 1.6m
Andrew Colin	Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board	11.8yrs	Nessun dato	Nessun dato
Yoori Lee	Independent Director	6.8yrs	US$51.30k	0.018% € 6.2k
Robert Carey	Independent Director	5.8yrs	US$102.60k	6.31% € 2.2m
Ron Bentsur	Independent Director	7.8yrs	US$51.30k	0.20% € 70.4k
William Forbes	Independent Director	6.3yrs	US$51.30k	0.021% € 7.2k
Yossef Av-Gay	Member of Scientific Advisory Board	6.8yrs	US$75.00k	Nessun dato
David Greenberg	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Richard Malley	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Erick Lucera	Independent Director	7.3yrs	US$51.30k	0.060% € 21.2k
Hannah Blau	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Stacey Martiniano	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato

7.0yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 48L sono considerati esperti (durata media dell'incarico 7 anni).

Beyond Air Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Beyond Air, Inc., Annual General Meeting, Dec 09, 2024

Beyond Air Appoints David Webster as Chief Commercial Officer, Effective from July 8, 2024

Beyond Air, Inc., Annual General Meeting, Mar 08, 2024

Independent Director recently bought €1.8m worth of stock

Independent Director recently bought €224k worth of stock

Independent Director recently bought €117k worth of stock

Recent updates

Beyond Air, Inc. announced that it has received $3.35 million in funding from Avenue Capital Group, LLC

Second quarter 2025 earnings released: US$0.28 loss per share (vs US$0.51 loss in 2Q 2024)

New major risk - Shareholder dilution

Beyond Air, Inc. to Report Q2, 2025 Results on Nov 11, 2024

Beyond Air, Inc., Annual General Meeting, Dec 09, 2024

Beyond Air, Inc. Withdraws Its Previous Revenue Guidance for Fiscal Year 2025

Beyond Air, Inc. Provides Earnings Guidance for the Year 2025

Beyond Air, Inc. to Report Q1, 2025 Results on Aug 06, 2024

Beyond Air, Inc. announced that it has received $0.128 million in funding

Beyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Comp Value Index

New major risk - Financial position

Beyond Air, Inc. Updates Revenue Guidance for the Fiscal Year 2025

Beyond Air Appoints David Webster as Chief Commercial Officer, Effective from July 8, 2024

Beyond Air, Inc. to Report Q4, 2024 Results on Jun 24, 2024

Beyond Air, Inc. has completed a Follow-on Equity Offering in the amount of $16.000003 million.

Beyond Air, Inc. has filed a Follow-on Equity Offering in the amount of $16.000003 million.

New major risk - Financial position

Beyond Air, Inc. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Beyond Air, Inc., Annual General Meeting, Mar 08, 2024

Beyond Air, Inc. to Report Q3, 2024 Results on Feb 12, 2024

Independent Director recently bought €1.8m worth of stock

New major risk - Financial position

Beyond Air, Inc. to Report Q2, 2024 Results on Nov 13, 2023

Beyond Air, Inc. Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder

Independent Director recently bought €224k worth of stock

New minor risk - Market cap size

New major risk - Share price stability

No longer forecast to breakeven

Beyond Air, Inc. to Report Q1, 2024 Results on Aug 10, 2023

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

No longer forecast to breakeven

Beyond Air, Inc. announced that it expects to receive $40 million in funding

Beyond Air, Inc. to Report Q4, 2023 Results on Jun 22, 2023

Forecast to breakeven in 2026

Forecast to breakeven in 2026

Independent Director recently bought €117k worth of stock

Forecast to breakeven in 2026

CEO & Chairman of the Board recently bought €61k worth of stock

Independent Director recently bought €56k worth of stock

Beyond Air, Inc., Annual General Meeting, Mar 09, 2023

Beyond Air, Inc. to Report Q3, 2023 Results on Feb 09, 2023

Independent Director recently bought €110k worth of stock

Independent Director recently bought €167k worth of stock

Independent Director recently bought €284k worth of stock

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVOD-19 with LungFit® PRO in A Poster Presentation At IDWeek 2022

Beyond Air, Inc. to Report Q2, 2023 Results on Nov 08, 2022

Beyond Air, Inc. Announces Positive Data from At-Home Pilot Study in Patients with Refractory NTM Lung Infection Treated with (NO) Using the LungFit® GO at the CHEST Annual Meeting 2022

Beyond Air Announces Annals of the American Thoracic Society Published Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis

Beyond Air, Inc. to Report Q1, 2023 Results on Aug 11, 2022

Beyond Air, Inc. Appoints Michael Gaul as Chief Operating Officer

Independent Director recently bought €1.1m worth of stock

Beyond Air, Inc. Announces Executive Changes

No longer forecast to breakeven

Full year 2022 earnings released: US$1.68 loss per share (vs US$1.27 loss in FY 2021)

Beyond Air’s LungFit PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure

Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022

Beyond Air, Inc. to Report Q4, 2022 Results on Jun 16, 2022

Insufficient new directors

Beyond Air, Inc. Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

Independent Director recently bought €123k worth of stock

Insufficient new directors

Independent Director recently bought €158k worth of stock

Independent Director recently bought €121k worth of stock

Insufficient new directors